Denosumab Efficacy for Periprosthetic Bone Mineral Density After Total Hip Arthroplasty

Previous meta-analyses have demonstrated that both denosumab and zoledronate significantly reduce periprosthetic bone mineral density (BMD) loss after total hip arthroplasty (THA), particularly in the proximal femur, and improve hip joint function. A previous study comparing anti-osteoporotic drugs for total hip BMD in postmenopausal women ranked denosumab as the most effective, followed by zoledronate and teriparatide. This study addresses the lack of data on denosumab at 6 months and confirms its superior efficacy in reducing periprosthetic BMD loss after THA, supporting previous findings.